Open an account

Citius Oncology

CTOR · NASDAQ

$0.671−$0.0394 (−5.55%)TodayMarket closed ·
Prev close $0.7104

About CTOR

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Employees
0
Headquarters
Cranford, New Jersey
Listed
Oct 14, 2022
Sector
Health Care
Industry
Biotechnology
Website
citiusonc.com

CTOR key statistics

Market cap
62.39M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
83.40K
Volume
97.45K
Open price
$0.73
High today
$0.7467
Low today
$0.6601
52 Week high
$1.95
52 Week low
$0.4912

Citius Oncology (CTOR) at a glance

As of Oct 20, 2026, Citius Oncology (CTOR) shares are priced at $0.671, giving the company a market cap of 62.39M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6601 and $0.7467. The current price is 1.7% above the day's low and 10.1% below its high.

Volume so far is 97.45K shares, in line with the average of 83.40K shares a day.

Over the past year Citius Oncology has ranged from $0.4912 to $1.95, and now sits 12% of the way up that range.

Citius Oncology met or beat analyst EPS estimates in 3 of the last 7 quarters. In Q3 FY26 it reported -$0.08 per share against an estimate of -$0.0816.

CTOR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 7 quarters, by 33.6% on average.

  1. Q1 FY25: reported -$0.09 per share against an estimate of -$0.0612
  2. Q2 FY25: reported -$0.11 per share against an estimate of -$0.0918
  3. Q3 FY25: reported -$0.08 per share against an estimate of -$0.153
  4. Q4 FY25: reported -$0.06 per share against an estimate of -$0.1224
  5. Q1 FY26: reported -$0.06 per share against an estimate of $0.0612
  6. Q2 FY26: reported -$0.27 per share against an estimate of -$0.0102
  7. Q3 FY26: reported -$0.08 per share against an estimate of -$0.0816

CTOR news

  • Press releasePRNewswire

    Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

  • Press releasePRNewswire

    Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releasePRNewswire

    Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

  • Press releasePRNewswire

    Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

  • Press releasePRNewswire

    Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Similar companies

Companies in the same industry as Citius Oncology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.